Compare PIPR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | BLCO |
|---|---|---|
| Founded | 1895 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | 2003 | 2022 |
| Metric | PIPR | BLCO |
|---|---|---|
| Price | $299.06 | $18.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $362.50 | $18.55 |
| AVG Volume (30 Days) | 200.4K | ★ 452.4K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 15.82 | N/A |
| Revenue | $1,904,217,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $13.09 | $7.45 |
| Revenue Next Year | $14.76 | $5.49 |
| P/E Ratio | $18.90 | ★ N/A |
| Revenue Growth | ★ 24.33 | 6.47 |
| 52 Week Low | $202.91 | $10.45 |
| 52 Week High | $380.26 | $18.92 |
| Indicator | PIPR | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 56.00 |
| Support Level | $248.90 | $16.35 |
| Resistance Level | $347.70 | N/A |
| Average True Range (ATR) | 14.28 | 0.64 |
| MACD | -2.62 | 0.07 |
| Stochastic Oscillator | 16.16 | 63.79 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.